Sera Prognostics EV/EBIT

Mitä Sera Prognostics tekee? Sera Prognostics, Inc. generates revenue through its commercial product, the PreTRM test, which predicts the risk of premature delivery in pregnant women carrying a single fetus during weeks 18 or 20 of gestation. The company's proteomics and bioinformatics platform identifies protein biomarkers in blood to forecast pregnancy complications, including preeclampsia, gestational diabetes mellitus, and fetal growth restriction. Healthcare providers and hospitals purchase the PreTRM test for prenatal care, targeting high-risk pregnancies to manage delivery timing and improve outcomes. The firm's pipeline of biomarker-based tests addresses multiple pregnancy-related conditions, expanding its diagnostic offerings in maternal health. The PreTRM test is a non-invasive blood-based diagnostic tool used by healthcare professionals to assess preterm birth risk, positioning Sera Prognostics as a provider of personalized pregnancy diagnostics. Its platform enables the discovery of validated protein biomarkers, which form the basis for its current and future products. The company's focus on blood-based biomarkers for pregnancy complications differentiates its offerings in the maternal health market, appealing to obstetricians and clinics seeking accurate predictive tools. Sera Prognostics' revenue model relies on the sale of the PreTRM test to medical institutions, with its pipeline including additional tests for conditions like postpartum depression and stillbirth. The company's diagnostic solutions are designed for use during specific gestational weeks, ensuring targeted application in prenatal care. By leveraging proteomics and bioinformatics, Sera Prognostics delivers predictive insights that help healthcare providers manage pregnancy risks effectively. Sera Prognostics on yksi Eurpooliin suosituimmista yhtiöistä.